RRMS: Disease PROgression and Myeloid Profiling After Bone Marrow TRANSPLANTation and Second Line Therapies

Recruiting now

Conditions studied: Multiple Sclerosis

In brief

To study whether highly effective therapies can halt disease progression in people with multiple sclerosis by modulating the peripheral myeloid landscape.

Key facts

Study ID

NCT06267781

Run by

IRCCS San Raffaele

People needed

30

Starts

2022-09-02

Expected to finish

2027-09-02

Last updated by the study team

2024-02-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years;
• Signed written informed consent;
• A diagnosis of RRMS according to the 2017 Revisions of the McDonald Criteria;
• High clinical and magnetic resonance imaging (MRI) inflammatory disease activity (at least 2 clinical relapses, or one clinical relapse with gadolinium (Gd)- enhancing or new T2 MRI lesions at a separate time point, in the previous 12 months)
• Patients referred for pharmacological treatment with aHSCT, alemtuzumab or ocrelizumab /ofatumumab, according to clinical practice following the Italian pharmacological regulatory agency (AIFA) criteria and guidelines and recommendations from the European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE);

You may not qualify if…

• Diagnosis of PPMS or SPMS according to the 2017 McDonald criteria
• Known intolerances/allergies to the active substance or the excipients contained in the DMT and/or contraindications according to product information

Where it is running

• IRCCS San Raffaele — Milan, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.